← Back to Analyst Consensus 
PALI Buy
PALISADE BIO, INC.
Current Price —
Implied Upside —
Analysts 16
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 1 reiterations from 2 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 13, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Oct 9, 2026 | Raymond James | initiate | — → Outperform | — | 54% |
| Sep 23, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jul 23, 2026 | Oppenheimer | initiate | — → Outperform | — | 52% |
| Apr 9, 2026 | Wolfe Research | initiate | — → Outperform | — | 54% |
| Mar 26, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Feb 25, 2026 | Stifel | initiate | — → Buy | $5 | 53% |
| Jan 9, 2026 | B. Riley Securities | initiate | — → Buy | $7 | 54% |
| Dec 30, 2025 | Clear Street | initiate | — → Buy | $12 | 48% |
| Dec 29, 2025 | Piper Sandler | initiate | — → Overweight | $25 | 54% |
| May 13, 2025 | Brookline Capital | maintain | Buy → Buy | $16 | 38% |
| Nov 20, 2024 | Brookline Capital | initiate | — → Buy | $38 | 38% |
| Nov 13, 2024 | Maxim Group | maintain | Buy → Buy | $8 | 42% |
| May 1, 2024 | Maxim Group | reiterate | Buy → Buy | $22.5 | 42% |
| Apr 16, 2024 | Maxim Group | maintain | Buy → Buy | $22.5 | 42% |
| Nov 17, 2023 | Maxim Group | upgrade | Hold → Buy | $1.5 | 42% |
| May 16, 2023 | Ladenburg Thalmann | maintain | Buy → Buy | $16 | 45% |
| Mar 30, 2023 | Maxim Group | upgrade | Hold → Buy | $50 | 42% |
Price Target Trend
Apr 29, 2026 Oct 26, 2026
EPS Estimates
0y —
0q —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days